Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 8/20 | 0.33 |
| ▸ | ACLY | P53396 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 5/20 | 0.32 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6864080 | 0.97 | TSHR (0.35) | TSHRALDH1A1TP53FAAHACLY | |
| Trifluoroacetic Acid SCHEMBL4163974 | 0.94 | ALDH1A1 (0.41) | TSHRALDH1A1TP53FAAHACLY | |
| Trifluoroacetic Acid SCHEMBL19552090 | 0.94 | ALDH1A1 (0.41) | TSHRALDH1A1TP53FAAHACLY | |
| Trifluoroacetic Acid SCHEMBL4809831 | 0.94 | ALDH1A1 (0.41) | TSHRALDH1A1TP53FAAHACLY | |
| Trifluoroacetic Acid SCHEMBL3634014 | 0.94 | ALDH1A1 (0.41) | TSHRALDH1A1TP53FAAHACLY | |
| Trifluoroacetic Acid SCHEMBL19552101 | 0.94 | ALDH1A1 (0.41) | TSHRALDH1A1TP53FAAHACLY | |
| Trifluoroacetic Acid SCHEMBL60574 | 0.94 | ALDH1A1 (0.41) | TSHRALDH1A1TP53FAAHACLY | |
| Trifluoroacetic Acid SCHEMBL9632138 | 0.94 | ALDH1A1 (0.41) | TSHRALDH1A1TP53FAAHACLY | |
| Trifluoroacetic Acid SCHEMBL1525100 | 0.94 | ALDH1A1 (0.41) | TSHRALDH1A1TP53FAAHACLY | |
| Trifluoroacetic Acid SCHEMBL4604829 | 0.91 | FFAR3 (0.41) | TSHRALDH1A1TP53FAAHACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117665191-B | Method for detecting quality of effective components in known cellulitis particles | 唐宁医药科技(济南)有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-117665191-A | Method for detecting quality of effective components in known cellulitis particles | 唐宁医药科技(济南)有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-111138337-B | Bicyclo [4.1.0] heptane nitrosourea derivatives for bioorthogonal reaction and preparation method and application thereof | 清华大学 | 2021-06-22 | — | — | CN | disclosed |
| CN-111138337-A | Bicyclo [4.1.0] heptane nitrosourea derivatives for bioorthogonal reaction and preparation method and application thereof | 清华大学 | 2020-05-12 | — | — | CN | disclosed |
| CN-107629098-A | Oleanolic acid type saponin class compound and combinations thereof | 苏州大学 | 2018-01-26 | — | — | CN | disclosed |
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| EP-1786786-A1 | ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2007-05-23 | — | — | EP | disclosed |
| CN-1284781-C | Polycyclic compounds with antitumor activity | HOFFMANN LA ROCHE (CH) | 2006-11-15 | — | — | CN | disclosed |
| WO-2006025783-A1 | ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
| EP-1436293-B1 | POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2006-02-01 | — | — | EP | disclosed |
| US-20030229098-A1 | Polycyclic compounds exhibiting anti-tumor activities | F.HOFFMANN-LA ROCHE AG (CH) | 2003-12-11 | — | — | US | disclosed |
| WO-2003093265-A1 | DIMERIC POLYCYCLIC COMPOUNDS FOR THE TREATMENT OF TUMORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-13 | — | — | WO | disclosed |
| US-6605618-B2 | Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction | WYETH | 2003-08-12 | — | — | US | disclosed |
| US-20030073691-A1 | Polycyclic compounds | HOFFMANN-LA ROCHE INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003031444-A1 | POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-17 | — | — | WO | disclosed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
| US-5273885-A | Using a polyiodothyronine analog of a phenyl compound containing a hydroxyl group ortho to an iodine | SYNTEX (U.S.A.) INC. (US) | 1993-12-28 | — | — | US | disclosed |
| EP-0332387-B1 | Triazole derivatives, their preparation and their use as fungicides | SANKYO CO (JP) | 1993-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073691-A1 | Polycyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, PKD1 | TSHR 2557/4885ALDH1A1 1636/4885TP53 5/4885 |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | TSHR 603/4885ALDH1A1 725/4885TP53 4790/4885 |
| US-20030229098-A1 | Polycyclic compounds exhibiting anti-tumor activities | RB1, CCNA1, ACIN1 | TSHR 2461/4885ALDH1A1 642/4885TP53 6/4885 |
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ADORA1, P2RX1, P2RY1 | TSHR 921/4885ALDH1A1 744/4885TP53 1922/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | TSHR 552/4885ALDH1A1 524/4885TP53 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.